Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Biophytis ( (BPTSY) ) is now available.
On September 15, 2025, Biophytis SA announced securing public funding in Brazil for its Phase 2 trial of BIO101, targeting muscle wasting associated with obesity. The company has partnered with prominent Brazilian clinical centers, FARMAVAX-UFMG and FMRP-USP, to facilitate patient recruitment and leverage local expertise. This development marks a strategic milestone, offering financial de-risking through non-dilutive funding from EMBRAPII and operational acceleration, reinforcing Biophytis’s credibility in the field and enhancing its potential to address a significant global therapeutic market.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.
Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Its lead drug candidate, BIO101, is a small molecule in development for muscular diseases such as sarcopenia and metabolic disorders like obesity. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Biophytis is listed on Euronext Growth Paris and the OTC market.
Technical Sentiment Signal: Sell
Current Market Cap: $4.75M
For an in-depth examination of BPTSY stock, go to TipRanks’ Overview page.